Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
Year: 2022
Type: article
Study design: Observational Study
Source: Blood
Authors: Ajay Major, Jovian Yu, Navika D. Shukla, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie G Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J Slade, Nathan Singh, Nausheen Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, University of Colorado Cancer Center, City Of Hope National Medical Center, City of Hope, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Emory University, Winship Cancer Institute, Cleveland Clinic, Mayo Clinic, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Utah, Huntsman Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, University of Minnesota, Masonic Cancer Center, Washington University in St. Louis, Alvin J. Siteman Cancer Center, The University of Kansas Cancer Center, University of Kansas Medical Center, University of Chicago Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310103706